Nektar TherapeuticsNKTR
13F holders, Q2 2026 (June 30)1holders −7
0new positions
7sold out
$1.00avg. 13F price*
At the end of Q2 2026, 1 institutions reported holding Nektar Therapeutics (NKTR) in their 13F filings, down 7 from Q1 2026. 0 opened new positions and 7 sold out. The largest holder was Huntington National Bank ($1).
- Company
- Nektar Therapeutics
- CUSIP
- 640268108
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 7 | $13K |
All 13F filers, Q1 2026 → Q2 2026: 186 shares sold, net −186 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 1 holders
| Huntington National Bank | 0.00% | No change | 1 | $1 |
"% of holder's portfolio" is NKTR's weight in each manager's 13F, not the share of Nektar Therapeutics the manager owns.